High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme
- 1Translational Gastroenterology Unit, Oxford University Hospitals NHS Trust, Oxford, UK
- 2Department of Colorectal Surgery, Oxford University Hospitals NHS Trust, Oxford, UK
- 3Bowel Cancer Screening, Oxford University Hospitals NHS Trust, Oxford, UK
- Correspondence to Dr. James E. East, Translational Gastroenterology Unit, Experimental Medicine Division, Nuffield Dept of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK; jameseast6{at}yahoo.com
- Accepted 5 July 2012
- Published Online First 31 July 2012
Two papers have recently been published in Gut by Boparai et al.1 and Edelstein et al.2 regarding the risks of hyperplastic polyposis syndrome (HPS), also called serrated polyposis. Both suggest a substantial cancer risk and continued development of serrated polyps associated with the syndrome. Previous reports have suggested that the prevalence of hyperplastic polyposis syndrome is relatively low in the general population (1:3000; 0.033%)3 with recent correspondence in Gut from Orlowska4 on this issue suggesting even lower levels (1:100 000). However, we noticed a number of cases during bowel cancer screening colonoscopy based on guaiac faecal occult blood testing (gFOBT) and, therefore, formally assessed this within our screening cohort in an audit as part of service development. Currently, the NHS Bowel Cancer Screening Programme (BCSP) …
